GSK claims lead in Ph3 respiratory drug race

Novartis says that its closely watched asthma and COPD drug QMF149 will be delayed, pushing back a planned filing to 2014. And that means that GSK's next-gen respiratory drug may well get to the marketplace first. GSK has high hopes for Relovair, which is in late-stage development with Theravance. "I'm pretty confident, having seen what's going on elsewhere, we have every chance to now be the first to market with the next-generation of respiratory molecules, in combination, in major markets," GSK Chief Executive Andrew Witty told reporters. Story

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.